Assertio Holdings (ASRT) Long-Term Deferred Tax (2022 - 2023)
Assertio Holdings' (ASRT) quarterly Long-Term Deferred Tax came in at $81.6 million in Q2 2023, little changed quarter-over-quarter from $81.6 million in Q1 2023.
Assertio Holdings (ASRT) Long-Term Deferred Tax (2022 - 2023) Analysis & Trends
Assertio Holdings has disclosed Long-Term Deferred Tax across 2 years of filings, most recently posting $81.6 million for Q2 2023.
- Long-Term Deferred Tax for Q2 2023 came in at $81.6 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2023 was $81.6 million (changed N/A YoY), and the FY2022 annual result was $80.2 million, changed N/A from the prior year.
- Long-Term Deferred Tax came in at $81.6 million for Q2 2023 at Assertio Holdings, roughly flat from $81.6 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $81.6 million in Q2 2023 to a low of $80.2 million in Q4 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Assertio Holdings | 150.94 Mn | 79.37 Mn | 7.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 81.59 Mn |
| Mar 31, 2023 | 81.57 Mn |
| Dec 31, 2022 | 80.20 Mn |